Equity
-€102,374
Debts exceed assets in financial year 2025.
Impact Omics
Overview
Lifetime
4 annual accounts with figures on one time axispeak €145,874 (2023)
€79,479▲ €165,226
lowest -€318,668 (2024)
-€138,281▲ €180,386
peak €57,825 (2023)
-€102,374▲ €158,469
€204,723▼ 41.6%
Board2 names since 2022
1 directorCURIOSITER
Documentsfilings and deeds
13-07-202618 days before the deadline
2025micro format
Gross margin from -€85,747 to €79,479Loss of €138,281Appointment: VGD Bedrijfsrevisoren BV (company auditor) 06-10Equity from -€260,842 to -€102,374Debts from €350,627 to €204,723Cash from €8,129 to €22,643
Key points
from the 2025 annual accountsLosses
-€795,624 in four years
Every financial year from 2022 to 2025 closed with a loss. 2024 was the heaviest.
Turnover
≈ €220,000 estimated
The micro format states no turnover.
Debts
€204,723 200% of the balance sheet
Financial debts 70%Suppliers 15%Taxes and wages 4%Other 12%
Of this, €61,748 falls due within a year.
Liquidity
1.12 was 0.28 in 2024
Short-term debts fell from €202,264 to €61,748.
Position in the sector
-100.0%
Lower solvency than 95% of companies in human health. Sector median 63.0% · 20,760 companies.
Checked score
54
Fair
Financially stronger than 26% of micro companies in human health (NACE 86)
Probability in this band: 1.5% to 4.2%
Negative equity caps the score at 59.
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,185 companies (NACE 86, micro).
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: < 0.1%▼ -0.1 percentage points vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.1%▲ +0.1 percentage points vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.6%▲ +0.5 percentage points vs 09-2025
11-2025: 0.6%● unchanged vs 10-2025
12-2025: 0.6%● unchanged vs 11-2025
01-2026: 0.6%● unchanged vs 12-2025
02-2026: 0.6%● unchanged vs 01-2026
03-2026: 0.7%▲ +0.1 percentage points vs 02-2026
04-2026: 0.7%● unchanged vs 03-2026
05-2026: 0.7%● unchanged vs 04-2026
06-2026: 0.8%▲ +0.1 percentage points vs 05-2026
07-2026: 0.8%● unchanged vs 06-2026highest value
08-2026: 0.3%▼ -0.5 percentage points vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026
11-2026: 0.3%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Capped at 59: negative equity
Negative equity -€102,374
Loss of €138,281, the second in a row (financial year 2025)
lowers risk
Sector: Human health activities (NACE 86)
Size: total assets €102,349
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 1% of them on solvency, 14% on liquidity, 5% on profitability and 83% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 7,639 companies had the same profile as Impact Omics has now. Each dot stands for 20 companies, two years later.
84.8%
were still trading
5.6%
stopped another way
8.8%
went bankrupt
Another 0.8% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Impact Omics itself is lower: 0.3% within 12 months. It rests on far more data about Impact Omics than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 7,639 companies, not a prediction for Impact Omics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
No credit on open account
Liquidity is tight, with a current ratio of 1.12 (0.28 in 2024), below the usual 1.5. Short-term debt is 60.3% and cash 22.1% of total assets. Equity is negative.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
22232425
2022 to 2025 · latest year -€102,374
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 13-07-2026, 18 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
18 days early
2024
48 days late
2023
29 days early
2022
11 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 4 accounts on average 3 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 17 July (3 of the last 4 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Appointment: VGD Bedrijfsrevisoren BV (company auditor)
259 new shares · 230 new shares · 212 new shares · General meeting of 19-09-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0779683030
Capital contribution of €220,000
Issue of 440 shares · Issue of 347 shares · 477 shares · General meeting of 28-09-2023 · Gazette deed
Incorporation
Founding capital of €7,500, 1,000 shares · Founder: VERGAUWE Nicolas Hannes Roger (comparant oprichter) · Appointment: CURIOSITER (director) · published on 06-01-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Impact Omics Tongeren-Borgloon | €102,349 | €79,479 | -100.0% | - |
| Meditech Imaging Society Charleroi | €93,404 | €60,081 | 39.5% | - |
| BY A TECHNOLOGIST Evere | €154,272 | €76,729 | 60.7% | - |
| MATSEN LIFE SCIENCES Londerzeel | €73,064 | €59,455 | 96.3% | - |
| LAHEMA Meise | €134,646 | €65,155 | 84.1% | - |
| BIOLAU Rixensart | €167,590 | €92,713 | 3.0% | - |
| ANALYSE SCHOTTE Bornem | €129,486 | €99,128 | 40.1% | - |
These companies have the same main activity as Impact Omics: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €73,100 and €168,000, founded between 2019 and 2023.
Official details
Source: KBO- Status
- Active since 04-01-2022Normal situation
- Activity
- Medical imaging and medical laboratoriesNACE 86910and 2 others
- Joint committee
- 330Health institutions and services · annual accounts 2025
- Establishment unit
- 2.327.225.2853001 Leuven, since 04-01-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Annual accounts 2025
- €79,479
- €138,281▼ 56.6%
- -€102,374▲ 60.8%
- €102,349▲ 14.0%
- Employeeson 31-12-2025
- 1=
- Filing
- Filed on 13-07-2026, 18 days before the end of the filing period
Insights on Impact Omics
Impact Omics files the micro format. That format states no turnover. The gross margin rose from -€97,136 in 2022 to €79,479 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
micro format, filed on 13-07-2026, 18 days before the deadline€79,479
▲ €165,226
-€131,182
▲ €192,054
-€138,281
▲ €180,386
€7,626
▲ €154,011
-100.0%
▲ 190.5 percentage points
1.12
▲ 0.85
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €220,000. Estimated: probably between €140,000 and €320,000.
Balance sheet
balance sheet total €102,349 on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
-100.0%
Lower than 95% of 20,760 companies in 2025.
1.12
Higher than 24% of 20,335 companies in 2025.
-135.1%
Lower than 95% of 20,616 companies in 2025.
Impact Omics
Middle half of the sector
80% of the sector
Micro accounts in human health (NACE 86)
Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: bottom quarter · Working capital: bottom quarter
Staff
€50,932
Staff costs divided by the average number of full-time equivalents.
people who joined
people who left
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet: assets | |||||
20/58 |
102,349 | 89,785 | 277,165 | 50,449 | |
21/28 |
32,975 | 33,906 | 32,717 | 12,379 | |
22/27 |
32,975 | 33,906 | 32,717 | 12,379 | |
23 |
32,975 | 33,906 | 32,717 | 12,379 | |
29/58 |
69,374 | 55,879 | 244,447 | 38,070 | |
40/41 |
46,730 | 47,751 | 39,287 | 12,502 | |
40 |
10,566 | 9,249 | 10,873 | 2,431 | |
41 |
36,165 | 38,501 | 28,414 | 10,071 | |
54/58 |
22,643 | 8,129 | 204,822 | 25,567 | |
490/1 |
- | - | 339 | - | |
| Balance sheet: equity and liabilities | |||||
10/49 |
102,349 | 89,785 | 277,165 | 50,449 | |
10/15 |
-102,374 | -260,842 | 57,825 | -174,378 | |
10/11 |
693,250 | 396,500 | 396,500 | 7,500 | |
14 |
-795,624 | -657,342 | -338,675 | -181,878 | |
17/49 |
204,723 | 350,627 | 219,340 | 224,828 | |
17 |
142,304 | 147,156 | - | - | |
170/4 |
142,304 | 147,156 | - | - | |
42/48 |
61,748 | 202,264 | 219,340 | 224,828 | |
42 |
12,696 | 162,844 | 165,000 | 200,000 | |
44 |
30,782 | 28,113 | 49,636 | 24,828 | |
440/4 |
30,782 | 28,113 | 49,636 | 24,828 | |
46 |
- | 444 | - | - | |
45 |
7,187 | 10,804 | 4,703 | - | |
450/3 |
202 | 90 | - | - | |
454/9 |
6,986 | 10,714 | 4,703 | - | |
47/48 |
11,082 | 59 | - | - | |
492/3 |
671 | 1,207 | - | - | |
| Income statement | |||||
9900 |
79,479 | -85,747 | 145,874 | -97,136 | |
62 |
50,932 | 56,419 | 35,876 | - | |
630 |
159,667 | 180,622 | 271,458 | 87,325 | |
640/8 |
62 | 449 | 384 | 348 | |
9901 |
-131,182 | -323,236 | -161,845 | -184,808 | |
75/76B |
144 | 15 | - | 52 | |
75 |
144 | 15 | - | 52 | |
65/66B |
12,432 | 2,242 | 8,729 | 21 | |
65 |
12,432 | 2,242 | 8,729 | 21 | |
9903 |
-143,471 | -325,463 | -170,574 | -184,777 | |
67/77 |
-5,189 | -6,795 | -13,777 | -2,899 | |
9904 |
-138,281 | -318,668 | -156,797 | -181,878 | |
9905 |
-138,281 | -318,668 | -156,797 | -181,878 | |
| Appropriation of the result | |||||
9906 |
-795,624 | -657,342 | -338,675 | -181,878 | |
14P |
-657,342 | -338,675 | -181,878 | - | |
| Social balance sheet | |||||
9087 |
1 | 1 | 0.8 | - | |
Hours worked1013 |
1,128 | 1,776 | 1,176 | - | |
| Document | |||||
The notes to these accounts have 11 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 13-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankSubsidies and aid
Flemish government 2023 to 2024, 2 entries, €220,531 awarded, €220,531 paid
| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2024 | 1 | -€19,020 | €29,531 |
| 2023 | 1 | €239,551 | €191,000 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| 28,485 | -142,614 | 109,614 | -97,484 | ||
| 21,386 | -138,046 | 114,662 | -94,554 | ||
| 158,737 | 181,810 | 291,796 | 99,704 | ||
| 14,515 | -196,693 | 179,254 | - | ||
| 7,626 | -146,385 | 25,108 | -186,758 | ||
| -100.0% | -290.5% | 20.9% | -345.7% | ||
| 1.12 | 0.28 | 1.11 | 0.17 | ||
| - | - | 3.79 | - | ||
| - | - | -271.2% | - | ||
| -135.1% | -354.9% | -56.6% | -360.5% | ||
| 2.29 | -63.61 | 12.56 | -4707.09 |
Debt to equity is not shown because equity is negative. Debt divided by negative equity means nothing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 |
|---|---|---|---|
| Employees at the balance-sheet date | 1 | 1 | 1 |
| full-time | 1 | 1 | 1 |
| in full-time equivalents | 1 | 1 | 1 |
| 1 | 1 | 0.8 | |
| On a permanent contract | 1 | 1 | 1 |
| Joined | - | - | 3 |
| Left | - | - | 2 |
Source: social balance sheet in the 2023 to 2025 annual accounts
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tangible fixed assets | €4,980 | €6,445 | €22,968 | €13,810 |
| Intangible fixed assets | €153,757 | €175,365 | €268,828 | €85,894 |
| €159,667 | €180,622 | €271,458 | €87,325 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Insights on Impact Omics
The operating result for 2025 is a loss of €131,182, smaller than the loss of €323,236 in 2024.
Equity is negative. Debt (€204,723) exceeds the balance-sheet total (€102,349).
Board & ownership
Board
1 director, 1 auditor, since incorporationCURIOSITER BV
Director, permanent representative VERGAUWE Nicolas Hannes Roger
appointed by deed of 06-01-2022
term without a fixed end
listed in the 2025 annual accounts, filed on 13-07-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 06-01-2022
Permanent representatives 1
VERGAUWE Nicolas Hannes Roger
Permanent representative, for CURIOSITER
appointed by deed of 06-01-2022
Mandates through the years
2 names, the dashed line is todayCURIOSITER
Director
Director
VGD Bedrijfsrevisoren BV
Company auditor
Company auditor
Board
Mandates as a list
- CURIOSITER
- Director, appointed by deed of 06-01-2022, still in office
- VGD Bedrijfsrevisoren BV
- Company auditor, appointed by deed of 06-10-2025, still in office
Control
Founder
VERGAUWE Nicolas Hannes Roger
This company
Impact Omics
Equity -€102,374
Loss €138,281 in 2025
Capital
- Contribution
- €693,250
- Shares
- 2,618 in the deed of 24-10-2023 and 3 later capital increases
- Contribution per share
- €265
- Equity per share
- -€39.10 in 2025
- Source
- 2025 annual accounts
Articles of association
deed of 06-01-2022 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Tenminste helft leden aanwezig of vertegenwoordigd, gewone meerderheid stemmen aanwezige of vertegenwoordigde bestuurders”
Shareholders
Contribution
deed of 24-10-2023 ↗
- Demcon Investment BV 477 shares
At incorporation
deed of 06-01-2022 ↗
- VERGAUWE Nicolas Hannes Roger 1,000 shares (100%) · in cash
Capital transactions
Capital over time
- 06-10-2025 Capital increase · 259 new shares · in cash
- 06-10-2025 Capital increase · 230 new shares · converteerbare lening
- 06-10-2025 Capital increase · 212 new shares · “twee leningen”
- 24-10-2023 Capital stated in the deed · 1,917 shares
- 06-01-2022 Incorporation · €7,500 · 1,000 shares
Network & group
No group
Impact Omics has no parent and no holdings in its annual accounts. CURIOSITER is the only director.
At the same address
Tongersesteenweg 15, 3840 Tongeren-Borgloon · 2 other companies| CURIOSITER
registered office since 23-04-2018 · founded in 2018 |
total assets €43,130 (2025) 0694.976.096 |
| Bers, Evelien (sole trader)
establishment since 01-09-2009 |
founded in 2009 0817.753.550 |
Connections & network
1 current directorThe network lets you explore the ties of Impact Omics.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Timeline
12 events since 2022Board
Capital
Filings
Financial
Establishments
20222023202420252026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBmicro format · 18 days before the deadline
2025
Liquidity more than quadruples current ratio 1.12 The current ratio rises from 0.28 to 1.12. Short-term debt falls from €202,264 to €61,748.
Appointment: VGD Bedrijfsrevisoren BV (company auditor)259 new shares · 230 new shares · 212 new shares · General meeting of 19-09-20257 points ▸
- General meeting, 19-09-2025
- Auditor appointment, VGD Bedrijfsrevisoren BV (company auditor)
- Auditor report, 18-09-2025
- Board meeting, 18-09-2025
- Share issue, €259
- 2,618 shares
- Amendment of the articles, article 5
- The deed holds 6 more points.
Annual accounts 2024 filed PDFmicro format · 48 days late
2024
Weakest financial year net -€318,668 The net result drops to -€318,668, the lowest from 2022 to 2025. It recovers the following year.
Annual accounts 2023 filed PDFmicro format · 29 days before the deadline
2023
Liquidity more than 6 times current ratio 1.11 The current ratio rises from 0.17 to 1.11. Short-term debt falls from €224,828 to €219,340.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0779683030
Capital contribution of €220,000Issue of 440 shares · Issue of 347 shares · 477 shares · General meeting of 28-09-20233 points ▸
- General meeting, 28-09-2023
- Capital contribution, €220,000
- 1,917 shares
- The deed holds 9 more points.
Annual accounts 2022 filed PDFmicro format · 11 days before the deadline
2022
IncorporationFounding capital of €7,500, 1,000 shares · Founder: VERGAUWE Nicolas Hannes Roger (comparant oprichter) · Appointment: CURIOSITER (director) · published on 06-01-20224 points ▸
- Founder, VERGAUWE Nicolas Hannes Roger (comparant oprichter)
- Founding capital, €7,500, 1,000 shares
- Director appointment, CURIOSITER
- Permanent representative, VERGAUWE Nicolas Hannes Roger
- The deed holds 3 more points.
First establishment Ambachtenlaan 1, Leuven
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Impact Omics was incorporated on 4 January 2022 as a private limited company by one natural person, with a starting capital of €7,500.12 In 2025 the capital was increased.3 CURIOSITER is director of the company, appointed by deed of 06-01-2022.2 Total assets rose from €50,449 in 2022 to €102,349 in 2025 and headcount from 0.8 full-time equivalents in 2023 to 1 in 2025.4
Company details
Identity
- Enterprise number
- 0779.683.030
- VAT number
- BE 0779.683.030
- Peppol ID
- 0208:0779683030
- Other Peppol ID
- 9925:BE0779683030
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 04-01-2022
- Financial year
- ends on 31 December
- Peppol
- Reachable since 24-11-2023Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- Impact Omics in Dutch
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 06-01-2022 (in Dutch)
- Name clauseThe company operates under this name according to its articles.
- Impact Omicsdeed of 06-01-2022 (in Dutch)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”deed of 06-01-2022 (in Dutch)
Activities
NACEBEL 202586910
Medical imaging and medical laboratories main activity
Joint committees annual accounts 2025
JC 330
Health institutions and services
Codes under NACEBEL 2008
86901
Human health activities main activity
72110
Scientific research and development
72190
Scientific research and development
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “De exploitatie van biologisch en chemische producten,processen,gegevens en technologieën voor de sector van de levenswetenschappen in het…”deed of 06-01-2022 (in Dutch)
5 activities
- De exploitatie van biologisch en chemische producten,processen,gegevens en technologieën voor de sector van de levenswetenschappen in het algemeen en de sector van de diagnostica in het bijzonder,zowel de humane als de veterinaire.Tevens kan de vennootschap actief zijn op het vlak van humane en veterinaire geneesmiddelen,nutraceutica,cosmetica,chemie en agroindustrie in het algemeen.Onder exploitatie wordt onder meer begrepen alle activiteiten van onderzoek,ontwikkeling,productie,marketing en commercialisatie
- Het onderzoeken en ontwikkelen van apparatuur,producten,testen,expertise en alle daarmee rechtstreeks of onrechtstreeks,geheel of gedeeltelijk,verbonden of gelieerde producten of diensten,voor de medische en gezondheidssector,daaronder begrepen doch daartoe niet beperkt de humane en veterinaire gezondheidszorg;de farmaceutische of parafarmaceutische of biomedische nijverheden,de diagnostica en therapeutica,de in vitro diagnostische activiteit,de meer algemene life science activiteit,de genetica,de micro- en nanotechnologie en dit alles in de meest ruime betekenis,alsook het ontwikkelen en uitvoeren van alle met het voornoemde rechtstreeks of onrechtstreeks,geheel of gedeeltelijk,verbonden of gelieerd onderzoek,systemen,testsystemen,testapparaten,producten en diensten
- Het produceren,fabriceren,industrialiseren en op gelijk welke wijze commercialiseren,exploiteren en distribueren van alle bovenvermelde producten,apparaten,testen,expertise en diensten en dit op rechtstreekse of onrechtstreekse wijze
- Het verwerven,kopen,verkopen,licentiëren,exploiteren en realiseren van intellectuele eigendomsrechten in het kader van de hierboven vermelde activiteiten
- De studie,de adviesverlening,het opbouwen en aanbieden van expertise,engineering en elke dienstverlening in het kader van de hierboven vermelde activiteiten
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Tongersesteenweg 15 registered office 3840 Tongeren-Borgloon | ||
| Ambachtenlaan 1 3001 Leuven | 04-01-2022 | 2.327.225.285 |
Buildings and parcels at the addresses
- Ground area
- 3,289 m²
- Buildings
- 974 m²
- Volume, LiDAR
- 5,984 m³
- Tallest building
- 13.8 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 24514C0015/00Z002 | 2,862 m² | 1 · 838 m² | 8.7 m · 2 |
| 73009C0592/00V000 | 427 m² | 1 · 136 m² | 13.8 m · 4 |